Zydus Life Science , a prominent pharmaceutical company, has announced encouraging results from its Epic-III Phase 2(B)/3 clinical trial of Saroglitazar Magnesium for the treatment of Primary Biliary Cholangitis (PBC). The study has yielded significant findings that could potentially reshape the landscape of PBC treatment.

Trial Results

The Epic-III trial, a crucial step in the drug development process, demonstrated a noteworthy biochemical response rate of 48.50% for Saroglitazar Magnesium. This impressive response rate indicates the drug's potential efficacy in managing PBC, a chronic liver disease that primarily affects the bile ducts.

Regulatory Outlook

Buoyed by these positive results, Zydus Lifesciences is gearing up for the next phase of drug development. The company has outlined its plans to submit Saroglitazar Magnesium for regulatory approval in the first quarter of 2026. This timeline suggests a strategic approach to compile comprehensive data and navigate the regulatory landscape.

Implications for PBC Treatment

Primary Biliary Cholangitis is a progressive liver disease that can lead to cirrhosis and liver failure if left untreated. The positive outcomes from the Saroglitazar Magnesium trial offer hope for PBC patients who may benefit from new treatment options.

Looking Ahead

As Zydus Lifesciences prepares for the regulatory submission, the medical community and patients alike will be keenly watching the progress of Saroglitazar Magnesium. If approved, this drug could potentially offer a new avenue for managing PBC, addressing an important unmet medical need in liver disease treatment.

The company's advancement in this area underscores its commitment to innovation in pharmaceutical development, particularly in the field of hepatology. As the regulatory process unfolds over the coming years, Zydus Lifesciences' Saroglitazar Magnesium may emerge as a significant player in the treatment of Primary Biliary Cholangitis.

Zydus Life Science , a prominent player in the pharmaceutical industry, has announced the passing of Mr. Samir Desai, President-BU Biologics and a key member of the company's senior management. The company informed the stock exchanges BSE and NSE about this development on August 26, 2025.

Senior Management Change

Mr. Samir Desai, who held the position of President-BU Biologics at Zydus Lifesciences, passed away on August 26, 2025. As a result, he ceases to be part of the company's senior management team. The company expressed profound grief in its communication to the stock exchanges.

In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Zydus Lifesciences provided the necessary details regarding this change in senior management.

Enhanced ESG Rating Performance

Zydus Lifesciences has received an improved Environmental, Social, and Governance (ESG) score for the financial year 2024-2025. SES ESG Research Private Limited has assigned the company an ESG score of 69.4, representing an improvement from the previous year's score of 67.8.

According to the rating framework, a score ranging between 60-70 is categorized as Medium Risk. The company noted that this rating was unsolicited, indicating an independent assessment of its ESG practices.

Regulatory Compliance and Disclosure

Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences, signed the communications to the stock exchanges. The ESG rating disclosure was made in compliance with Regulation 30 of the Listing Regulations, read with SEBI Circulars dated November 11, 2024, and December 31, 2024.

The company ensured timely disclosure of these significant events, maintaining transparency with its stakeholders and complying with regulatory requirements. While Zydus Lifesciences faces the challenge of losing a key member of its senior management team, the improved ESG score indicates the company's ongoing efforts to enhance its sustainability and governance practices.